
Celldex Therapeutics (CLDX) Stock Forecast & Price Target
Celldex Therapeutics (CLDX) Analyst Ratings
Bulls say
Celldex Therapeutics is supported by barzolvolimab’s compelling Phase 3 efficacy, including 42% to 46% Week 12 complete response rates that deepened to 45% to 54% at Week 24, plus strong activity in omalizumab-refractory and angioedema patients. Physicians in the survey still viewed the drug favorably, with 81% calling it somewhat or much more effective than current advanced therapies, while 89% expected to use it only after one or more prior advanced therapies, suggesting a pragmatic but durable adoption path. The safety profile appears manageable rather than disqualifying, as only two probable anaphylaxis cases occurred among more than 2,400 treated patients and 81% said neutropenia would not prevent prescribing, supporting a differentiated commercial opportunity in CSU and beyond.
Bears say
Celldex Therapeutics is exposed to substantial clinical and regulatory risk because its lead asset, barzolvolimab, is still in development for highly contested indications such as chronic spontaneous urticaria, chronic inducible urticaria, and atopic dermatitis, where patient recruitment delays could push results and approval timelines later than anticipated. The company also faces intense competition from established products and many clinical-stage agents, making it difficult to prove differentiation and gain adoption if clinicians remain committed to existing therapies. Because barzolvolimab accounts for the majority of its valuation, any weak data, regulatory pushback, or commercial execution missteps could materially impair the stock’s outlook.
This aggregate rating is based on analysts' research of Celldex Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Celldex Therapeutics (CLDX) Analyst Forecast & Price Prediction
Start investing in Celldex Therapeutics (CLDX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Celldex Therapeutics (CLDX) Forecast
Celldex Therapeutics (CLDX) Analyst Forecast & Price Prediction
Start investing in Celldex Therapeutics (CLDX)
Order type
Buy in
Order amount
Est. shares
0 shares